Review



anti mouse cd11c  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Miltenyi Biotec anti mouse cd11c
    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on <t>CD11c</t> + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Anti Mouse Cd11c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1220 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/CD11c+Antibody%2C+anti-mouse/pmc13335422-309-159-148
    Average 96 stars, based on 1220 article reviews
    anti mouse cd11c - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation"

    Article Title: Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation

    Journal: The Journal of Experimental Medicine

    doi: 10.1084/jem.20252201

    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on CD11c + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Figure Legend Snippet: CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on CD11c + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.

    Techniques Used: Flow Cytometry, Expressing, Enzyme-linked Immunosorbent Assay, Activation Assay, Marker, Comparison

    CAlleR 8 Tregs do not prevent immunoglobulin production or the activation of T cells and DCs. (A) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 4–7 from two independent experiments). (B) Total serum IgE quantification by ELISA ( n = 7–13 from two independent experiments). (C) Cumulative data on the percentage of DCs detected in the lungs (gated on CD11c + CD11b + F480 − MHC-II + ) ( n = 4–7 from two independent experiments). (D and E) Cumulative data of the percentage of the different T populations observed in (D) the lungs and in (E) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) ( n = 5–9 from two independent experiments). Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in A–C and with two-way ANOVA with Tukey’s multiple comparison test in D and E. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Figure Legend Snippet: CAlleR 8 Tregs do not prevent immunoglobulin production or the activation of T cells and DCs. (A) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 4–7 from two independent experiments). (B) Total serum IgE quantification by ELISA ( n = 7–13 from two independent experiments). (C) Cumulative data on the percentage of DCs detected in the lungs (gated on CD11c + CD11b + F480 − MHC-II + ) ( n = 4–7 from two independent experiments). (D and E) Cumulative data of the percentage of the different T populations observed in (D) the lungs and in (E) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) ( n = 5–9 from two independent experiments). Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in A–C and with two-way ANOVA with Tukey’s multiple comparison test in D and E. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.

    Techniques Used: Activation Assay, Enzyme-linked Immunosorbent Assay, Comparison

    CAlleR 8 murine Treg tissue–specific homing. (A) Experimental design of murine CAlleR 8 GFP + and CAR A2 GFP + Treg production. (B) Representative plots of Treg phenotype and transduction efficiency after 7 days of expansion. (C) Experimental design of the allergic airway inflammation mouse model and adoptive Treg transfer. (D) Representative images of CAlleR 8 and CAR A2 Tregs in the mLNs, lung, and spleen of mice exposed to PBS or BPE. White bars represent the scale of 20 μm, and small images show fluorescence channels of the magnified region outlined in white squares. (E) Cumulative data of detection of GFP + cells/mm2 in each organ ( n = 8 in the lung and spleen and n = 5–8 in mLN from four mice with image duplicates). (F) Cumulative data of the percentage of GFP + cells interacting with CD11c + , B220 + APCs or with none of them (no CD11c + /B220 + contact) for each organ ( n = 8 in the lung and spleen and n = 5–8 in the mLN from four mice with image duplicates). In E, data are represented by the median ± interquartile range and in F by the mean ± SEM. P values were calculated with Kruskal–Wallis and Dunn’s multiple comparison test in E and with two-way ANOVA with Tukey’s test in F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Figure Legend Snippet: CAlleR 8 murine Treg tissue–specific homing. (A) Experimental design of murine CAlleR 8 GFP + and CAR A2 GFP + Treg production. (B) Representative plots of Treg phenotype and transduction efficiency after 7 days of expansion. (C) Experimental design of the allergic airway inflammation mouse model and adoptive Treg transfer. (D) Representative images of CAlleR 8 and CAR A2 Tregs in the mLNs, lung, and spleen of mice exposed to PBS or BPE. White bars represent the scale of 20 μm, and small images show fluorescence channels of the magnified region outlined in white squares. (E) Cumulative data of detection of GFP + cells/mm2 in each organ ( n = 8 in the lung and spleen and n = 5–8 in mLN from four mice with image duplicates). (F) Cumulative data of the percentage of GFP + cells interacting with CD11c + , B220 + APCs or with none of them (no CD11c + /B220 + contact) for each organ ( n = 8 in the lung and spleen and n = 5–8 in the mLN from four mice with image duplicates). In E, data are represented by the median ± interquartile range and in F by the mean ± SEM. P values were calculated with Kruskal–Wallis and Dunn’s multiple comparison test in E and with two-way ANOVA with Tukey’s test in F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Techniques Used: Transduction, Fluorescence, Comparison

    Related Articles

    Purification:

    Article Title: Cryptococcus neoformans Enters the Endolysosomal Pathway of Dendritic Cells and Is Killed by Lysosomal Components
    Article Snippet: .. The cells were then purified by positive selection using magnetically labeled CD11c antibodies (Miltenyi Biotec, Auburn, CA). ..

    Article Title: Cryptococcus neoformans Enters the Endolysosomal Pathway of Dendritic Cells and Is Killed by Lysosomal Components
    Article Snippet: .. The cells were then purified by positive selection using magnetically labeled CD11c antibodies (Miltenyi Biotec, Auburn, CA). ..

    Selection:

    Article Title: Cryptococcus neoformans Enters the Endolysosomal Pathway of Dendritic Cells and Is Killed by Lysosomal Components
    Article Snippet: .. The cells were then purified by positive selection using magnetically labeled CD11c antibodies (Miltenyi Biotec, Auburn, CA). ..

    Article Title: Cryptococcus neoformans Enters the Endolysosomal Pathway of Dendritic Cells and Is Killed by Lysosomal Components
    Article Snippet: .. The cells were then purified by positive selection using magnetically labeled CD11c antibodies (Miltenyi Biotec, Auburn, CA). ..

    Labeling:

    Article Title: Cryptococcus neoformans Enters the Endolysosomal Pathway of Dendritic Cells and Is Killed by Lysosomal Components
    Article Snippet: .. The cells were then purified by positive selection using magnetically labeled CD11c antibodies (Miltenyi Biotec, Auburn, CA). ..

    Article Title: B orrelia p eptidoglycan i nteracting P rotein (BpiP) contributes to the fitness of Borrelia burgdorferi against host-derived factors and influences virulence in mouse models of Lyme disease
    Article Snippet: The cells were then purified by negative selection of F4/80 + cells using F4/80 biotin and anti-biotin beads (Miltenyi Biotec, Auburn, CA). .. The flow-through cells were further positively selected using magnetically labeled CD11c antibodies (Miltenyi Biotec). ..

    Article Title: Cryptococcus neoformans Enters the Endolysosomal Pathway of Dendritic Cells and Is Killed by Lysosomal Components
    Article Snippet: .. The cells were then purified by positive selection using magnetically labeled CD11c antibodies (Miltenyi Biotec, Auburn, CA). ..

    Incubation:

    Article Title: The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo
    Article Snippet: .. After washing, cells were incubated with magnetic beads coated with anti-mouse CD4, CD8, CD11b, and CD11c antibodies (Miltenyi Biotec, Auburn, CA), and cells binding to the beads were removed by AutoMACS (Miltenyi Biotec). .. Purified B cells were first incubated with anti-mouse CD16/CD32 mAb (BD Bioscience, San Diego, CA) to block Fcγ receptors, followed by FITC-anti-mouse IgD, FITC-anti-mouse IgM (Southern Biotech, Birmingham AL), PE-anti-mouse CD138, PerCP-Cy5.5-anti-mouse B220 antibodies (BD Bioscience) and NP 19 -APC at 4°C in FACS buffer (1% FBS, 20 mM EDTA, 0.02% NaN 3 in PBS).

    Article Title: Spatiotemporal dynamics of cytokines expression dictate fetal liver hematopoiesis
    Article Snippet: For sorting, FL were depleted of mature cells using MACS columns (Miltenyi Biotec) according to manufacturer instructions. .. Briefly, cells were incubated with biotinylated Ter119, Gr-1, CD19, CD3, CD4, CD8, NK1.1, CD11c antibodies (listed in ) for 20-30 min at 4°C, washed, incubated with anti-biotin microbeads (Miltenyi Biotec) for 20 min at 4°C and passed through a LS column (Miltenyi Biotec). ..

    Magnetic Beads:

    Article Title: The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo
    Article Snippet: .. After washing, cells were incubated with magnetic beads coated with anti-mouse CD4, CD8, CD11b, and CD11c antibodies (Miltenyi Biotec, Auburn, CA), and cells binding to the beads were removed by AutoMACS (Miltenyi Biotec). .. Purified B cells were first incubated with anti-mouse CD16/CD32 mAb (BD Bioscience, San Diego, CA) to block Fcγ receptors, followed by FITC-anti-mouse IgD, FITC-anti-mouse IgM (Southern Biotech, Birmingham AL), PE-anti-mouse CD138, PerCP-Cy5.5-anti-mouse B220 antibodies (BD Bioscience) and NP 19 -APC at 4°C in FACS buffer (1% FBS, 20 mM EDTA, 0.02% NaN 3 in PBS).

    Binding Assay:

    Article Title: The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo
    Article Snippet: .. After washing, cells were incubated with magnetic beads coated with anti-mouse CD4, CD8, CD11b, and CD11c antibodies (Miltenyi Biotec, Auburn, CA), and cells binding to the beads were removed by AutoMACS (Miltenyi Biotec). .. Purified B cells were first incubated with anti-mouse CD16/CD32 mAb (BD Bioscience, San Diego, CA) to block Fcγ receptors, followed by FITC-anti-mouse IgD, FITC-anti-mouse IgM (Southern Biotech, Birmingham AL), PE-anti-mouse CD138, PerCP-Cy5.5-anti-mouse B220 antibodies (BD Bioscience) and NP 19 -APC at 4°C in FACS buffer (1% FBS, 20 mM EDTA, 0.02% NaN 3 in PBS).

    Staining:

    Article Title: Penicillin Binding Proteins as Danger Signals: Meningococcal Penicillin Binding Protein 2 Activates Dendritic Cells through Toll-Like Receptor 4
    Article Snippet: .. BMDCs were stained with anti-CD40, MHC class II, CD80, CD86 and CD11c antibodies (BD Biosciences and Miltenyi Biotech). ..

    Immunopeptidomics:

    Article Title: Penicillin Binding Proteins as Danger Signals: Meningococcal Penicillin Binding Protein 2 Activates Dendritic Cells through Toll-Like Receptor 4
    Article Snippet: .. BMDCs were stained with anti-CD40, MHC class II, CD80, CD86 and CD11c antibodies (BD Biosciences and Miltenyi Biotech). ..



    Similar Products

    96
    Miltenyi Biotec anti mouse cd11c
    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on <t>CD11c</t> + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Anti Mouse Cd11c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/CD11c+Antibody%2C+anti-mouse/pmc13335422-309-159-148
    Average 96 stars, based on 1 article reviews
    anti mouse cd11c - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec reafinitytm
    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on <t>CD11c</t> + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Reafinitytm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/CD11c+Antibody%2C+anti-mouse/pmc13129426-3-3-10
    Average 96 stars, based on 1 article reviews
    reafinitytm - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec anti mouse
    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on <t>CD11c</t> + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Anti Mouse, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/CD11c+Antibody%2C+anti-mouse/pmc13129426-3-2-10
    Average 96 stars, based on 1 article reviews
    anti mouse - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd11c antibody
    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on <t>CD11c</t> + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Cd11c Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/CD11c+Antibody%2C+anti-mouse/pmc13129426-3-0-10
    Average 96 stars, based on 1 article reviews
    cd11c antibody - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec rea754
    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on <t>CD11c</t> + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Rea754, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/CD11c+Antibody%2C+anti-mouse%2C+REAfinity/pmc13129426-3-6-10
    Average 95 stars, based on 1 article reviews
    rea754 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec vioblue
    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on <t>CD11c</t> + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.
    Vioblue, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/CD11c+Antibody%2C+anti-mouse/pmc13129426-3-4-10
    Average 96 stars, based on 1 article reviews
    vioblue - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology fitc anti mouse cd11c
    SL disA increases the antigen-presentation capacity of dendritic cells (A) IFN-β levels in BMDC supernatants from media, SL, SL disA , and SL disA +H151 groups. (B, C) BMDCs double-stained with MHC II and <t>CD11c</t> were analyzed by flow cytometry (B), and CD11c + MHCII + cells are shown in the statistical graph (C). Data were expressed as mean ± SEM, n = 3. ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; one-way ANOVA with Tukey’s multiple comparisons tests.
    Fitc Anti Mouse Cd11c, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/FITC+Anti-Mouse+CD11c+Antibody/pmc13091351-198-11-16
    Average 94 stars, based on 1 article reviews
    fitc anti mouse cd11c - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec spleen cd11c n418
    FAM134B-mediated ER-phagy downregulates sepsis-induced ferroptosis to protect the immune response of DCs. Two types of mice were adopted the severe CLP. Mice in the control group were defined as a sham operation. A. The percentage of co-stimulatory phenotypes expressed on DCs was measured by flow cytometry. B. DCs from hemophthalmia of CLP mice were cocultured with CD4 + T cells stained with Con A, and then T-cell proliferation induced by DCs was measured by flow cytometry. C. The release of inflammatory cytokines reflecting the degree of DC maturity and secretion was detected by ELISA after CLP. D. The survival rates of WT mice (n = 11) and FAM134B -/- mice (n = 12) were monitored at the indicated time points. E-G. The conditional knockout of FAM134B targeted for splenic DC in mouse <t>(CD11c</t> cre FAM134B fl/fl ) was structured and then underwent CLP procedure. DCs immune functions was measured by Flow Cytometry and survival rates of septic mice were analyzed. Data from three independent experiments were exhibited as the mean ± SD (n = 3 per group). Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 vs. the WT-Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. the FAM134B -/- -Sham group; & P < 0.05, && P < 0.01, &&& P < 0.001 as the FAM134B -/- -CLP group vs. the WT-CLP group.
    Spleen Cd11c N418, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/CD11c+Antibody%2C+anti-mouse/pmc13131526-62-0-15
    Average 96 stars, based on 1 article reviews
    spleen cd11c n418 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd11c
    FAM134B-mediated ER-phagy downregulates sepsis-induced ferroptosis to protect the immune response of DCs. Two types of mice were adopted the severe CLP. Mice in the control group were defined as a sham operation. A. The percentage of co-stimulatory phenotypes expressed on DCs was measured by flow cytometry. B. DCs from hemophthalmia of CLP mice were cocultured with CD4 + T cells stained with Con A, and then T-cell proliferation induced by DCs was measured by flow cytometry. C. The release of inflammatory cytokines reflecting the degree of DC maturity and secretion was detected by ELISA after CLP. D. The survival rates of WT mice (n = 11) and FAM134B -/- mice (n = 12) were monitored at the indicated time points. E-G. The conditional knockout of FAM134B targeted for splenic DC in mouse <t>(CD11c</t> cre FAM134B fl/fl ) was structured and then underwent CLP procedure. DCs immune functions was measured by Flow Cytometry and survival rates of septic mice were analyzed. Data from three independent experiments were exhibited as the mean ± SD (n = 3 per group). Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 vs. the WT-Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. the FAM134B -/- -Sham group; & P < 0.05, && P < 0.01, &&& P < 0.001 as the FAM134B -/- -CLP group vs. the WT-CLP group.
    Cd11c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/Erythroid+Cells+Antibody%2C+anti-rat%2C+REAfinity/bio_rxiv__64898__2026__04__18__719387-179-44-51
    Average 96 stars, based on 1 article reviews
    cd11c - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology pe cd11c
    FAM134B-mediated ER-phagy downregulates sepsis-induced ferroptosis to protect the immune response of DCs. Two types of mice were adopted the severe CLP. Mice in the control group were defined as a sham operation. A. The percentage of co-stimulatory phenotypes expressed on DCs was measured by flow cytometry. B. DCs from hemophthalmia of CLP mice were cocultured with CD4 + T cells stained with Con A, and then T-cell proliferation induced by DCs was measured by flow cytometry. C. The release of inflammatory cytokines reflecting the degree of DC maturity and secretion was detected by ELISA after CLP. D. The survival rates of WT mice (n = 11) and FAM134B -/- mice (n = 12) were monitored at the indicated time points. E-G. The conditional knockout of FAM134B targeted for splenic DC in mouse <t>(CD11c</t> cre FAM134B fl/fl ) was structured and then underwent CLP procedure. DCs immune functions was measured by Flow Cytometry and survival rates of septic mice were analyzed. Data from three independent experiments were exhibited as the mean ± SD (n = 3 per group). Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 vs. the WT-Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. the FAM134B -/- -Sham group; & P < 0.05, && P < 0.01, &&& P < 0.001 as the FAM134B -/- -CLP group vs. the WT-CLP group.
    Pe Cd11c, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11c+antibodies/PE+Anti-Mouse+CD11c+Antibody/pm41984190-37-21-23
    Average 94 stars, based on 1 article reviews
    pe cd11c - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on CD11c + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.

    Journal: The Journal of Experimental Medicine

    Article Title: Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation

    doi: 10.1084/jem.20252201

    Figure Lengend Snippet: CAlleR 8 Tregs do not regulate immunoglobulin production or affect the T cell and dendritic cell compartments in the treatment model. (A) Representative flow cytometry plots showing the gating strategy for neutrophils, monocytes, and eosinophils in the lungs. The expression of SiglecF in lung eosinophils is also shown. (B) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 7–9 from two independent experiments). (C) Total serum IgE quantification by ELISA ( n = 6–10 from two independent experiments). (D) Gating strategy and cumulative data on the percentage of DCs detected in the lungs (gated on CD11c + CD11b + F480 − MHC-II + ) ( n = 7–10 from two independent experiments). (E and F) Cumulative data of the percentage of the different T populations observed in (E) the lungs and in (F) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) and representative plots and cumulative percentage of CD4 + T cells expressing the activation marker CD44 ( n = 7–10 from two independent experiments). (G) Representative flow cytometry plots showing intracellular expression of Th2 cytokines in lung CD4 + T cells. Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in B, C, and D and with two-way ANOVA with Tukey’s multiple comparison test in E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.

    Article Snippet: After blocking, cells were washed and extracellular staining was performed for 30 min at 4°C with the following antibodies: anti-mouse CD3 (145-2C11), PE-Cy7 (1:250 dilution) and APC-Cy7 (1:100 dilution), 552774; BD Biosciences (RRID:AB_394460) and 561042 (RRID:AB_2034003), respectively; anti-mouse CD4 (RM4-5), PerCP-Cy5.5 (1:300 dilution) and APC (1:250 dilution), 561090 and 553051; BD Biosciences, respectively; anti-mouse CD8a (53-6.7), FITC (1:100 dilution) and Pacific Blue (1:400 dilution), 553030 and 558106; BD Biosciences, respectively; anti-mouse CD25 (PC61.5), PE (1:200 dilution), 12-0251-83; Invitrogen; anti-mouse CD25 (PC61), PerCP-Cy5.5 (1:250 dilution), 551071; BD Biosciences; anti-mouse CD44 (IM7), FITC (1:100 dilution), 553133; BD Biosciences; anti-mouse CD45 (30-F11), PE-Cy7 (1:250), 552848; BD Biosciences; anti-mouse CD45.2 (104), AF700 (1:100 dilution), 109821; BioLegend; anti-mouse CD69 (H1.2F3), PE (1:400 dilution), 553237; BD Biosciences; anti-mouse CD86 (GL1), PE (1:250 dilution), 553692; BD Biosciences; anti-mouse CD90.1 (Thy1.1; OX-7), PerCP-Cy5.5 (1:250 dilution), 557266; BD Biosciences; anti-mouse CD90.1 (Thy1.1; REA838), FITC (1:500 dilution), 130-112-872; Miltenyi Biotech; anti-mouse CD11c (HL3), APC (1:100 dilution), 550261; BD Biosciences; anti-mouse CD11c (N418), APC-Cy7 (1:600 dilution), 117323; BioLegend; anti-mouse CD11b (M1/70), PECy7 (1:600 dilution), 561098; BD Biosciences; anti-mouse MHC-II (M5/114.15.2), AF700 (1:1,000 dilution), 107621; BioLegend; anti-mouse F480 (BM8), PerCP (1:100 dilution), 123126; BioLegend; anti-mouse Ly6C (HK1.4), Pacific Blue (1:1,000 dilution), 128013; BioLegend; anti-mouse SiglecF (E50-2440), PE (1:100 dilution), 562068; BD Biosciences; anti-mouse Ly6G (1A8), PerCP Cy5.5 (1:100 dilution), 560602; BD Biosciences; biotinylated rBet v1 (1 μg/ml); streptavidin, APC (1:500 dilution) and PE (1:1,000 dilution), 554067 and 554061; BD Biosciences, respectively; Aqua (Live/Dead), AmCyan (1:1,000 dilution), L34957 ; Invitrogen; DAPI (Live/Dead), Invitrogen (1:2,500 dilution), D1306.

    Techniques: Flow Cytometry, Expressing, Enzyme-linked Immunosorbent Assay, Activation Assay, Marker, Comparison

    CAlleR 8 Tregs do not prevent immunoglobulin production or the activation of T cells and DCs. (A) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 4–7 from two independent experiments). (B) Total serum IgE quantification by ELISA ( n = 7–13 from two independent experiments). (C) Cumulative data on the percentage of DCs detected in the lungs (gated on CD11c + CD11b + F480 − MHC-II + ) ( n = 4–7 from two independent experiments). (D and E) Cumulative data of the percentage of the different T populations observed in (D) the lungs and in (E) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) ( n = 5–9 from two independent experiments). Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in A–C and with two-way ANOVA with Tukey’s multiple comparison test in D and E. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.

    Journal: The Journal of Experimental Medicine

    Article Title: Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation

    doi: 10.1084/jem.20252201

    Figure Lengend Snippet: CAlleR 8 Tregs do not prevent immunoglobulin production or the activation of T cells and DCs. (A) Specific anti-Bet v1 IgG1 detection in mouse serum by ELISA ( n = 4–7 from two independent experiments). (B) Total serum IgE quantification by ELISA ( n = 7–13 from two independent experiments). (C) Cumulative data on the percentage of DCs detected in the lungs (gated on CD11c + CD11b + F480 − MHC-II + ) ( n = 4–7 from two independent experiments). (D and E) Cumulative data of the percentage of the different T populations observed in (D) the lungs and in (E) the mLN (CD3 + T cells, CD4 + , CD8 + , and Tregs) ( n = 5–9 from two independent experiments). Data are represented as the mean ± SEM, and P values were calculated with one-way ANOVA with Tukey’s multiple comparison test in A–C and with two-way ANOVA with Tukey’s multiple comparison test in D and E. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. DCs, dendritic cells.

    Article Snippet: After blocking, cells were washed and extracellular staining was performed for 30 min at 4°C with the following antibodies: anti-mouse CD3 (145-2C11), PE-Cy7 (1:250 dilution) and APC-Cy7 (1:100 dilution), 552774; BD Biosciences (RRID:AB_394460) and 561042 (RRID:AB_2034003), respectively; anti-mouse CD4 (RM4-5), PerCP-Cy5.5 (1:300 dilution) and APC (1:250 dilution), 561090 and 553051; BD Biosciences, respectively; anti-mouse CD8a (53-6.7), FITC (1:100 dilution) and Pacific Blue (1:400 dilution), 553030 and 558106; BD Biosciences, respectively; anti-mouse CD25 (PC61.5), PE (1:200 dilution), 12-0251-83; Invitrogen; anti-mouse CD25 (PC61), PerCP-Cy5.5 (1:250 dilution), 551071; BD Biosciences; anti-mouse CD44 (IM7), FITC (1:100 dilution), 553133; BD Biosciences; anti-mouse CD45 (30-F11), PE-Cy7 (1:250), 552848; BD Biosciences; anti-mouse CD45.2 (104), AF700 (1:100 dilution), 109821; BioLegend; anti-mouse CD69 (H1.2F3), PE (1:400 dilution), 553237; BD Biosciences; anti-mouse CD86 (GL1), PE (1:250 dilution), 553692; BD Biosciences; anti-mouse CD90.1 (Thy1.1; OX-7), PerCP-Cy5.5 (1:250 dilution), 557266; BD Biosciences; anti-mouse CD90.1 (Thy1.1; REA838), FITC (1:500 dilution), 130-112-872; Miltenyi Biotech; anti-mouse CD11c (HL3), APC (1:100 dilution), 550261; BD Biosciences; anti-mouse CD11c (N418), APC-Cy7 (1:600 dilution), 117323; BioLegend; anti-mouse CD11b (M1/70), PECy7 (1:600 dilution), 561098; BD Biosciences; anti-mouse MHC-II (M5/114.15.2), AF700 (1:1,000 dilution), 107621; BioLegend; anti-mouse F480 (BM8), PerCP (1:100 dilution), 123126; BioLegend; anti-mouse Ly6C (HK1.4), Pacific Blue (1:1,000 dilution), 128013; BioLegend; anti-mouse SiglecF (E50-2440), PE (1:100 dilution), 562068; BD Biosciences; anti-mouse Ly6G (1A8), PerCP Cy5.5 (1:100 dilution), 560602; BD Biosciences; biotinylated rBet v1 (1 μg/ml); streptavidin, APC (1:500 dilution) and PE (1:1,000 dilution), 554067 and 554061; BD Biosciences, respectively; Aqua (Live/Dead), AmCyan (1:1,000 dilution), L34957 ; Invitrogen; DAPI (Live/Dead), Invitrogen (1:2,500 dilution), D1306.

    Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Comparison

    CAlleR 8 murine Treg tissue–specific homing. (A) Experimental design of murine CAlleR 8 GFP + and CAR A2 GFP + Treg production. (B) Representative plots of Treg phenotype and transduction efficiency after 7 days of expansion. (C) Experimental design of the allergic airway inflammation mouse model and adoptive Treg transfer. (D) Representative images of CAlleR 8 and CAR A2 Tregs in the mLNs, lung, and spleen of mice exposed to PBS or BPE. White bars represent the scale of 20 μm, and small images show fluorescence channels of the magnified region outlined in white squares. (E) Cumulative data of detection of GFP + cells/mm2 in each organ ( n = 8 in the lung and spleen and n = 5–8 in mLN from four mice with image duplicates). (F) Cumulative data of the percentage of GFP + cells interacting with CD11c + , B220 + APCs or with none of them (no CD11c + /B220 + contact) for each organ ( n = 8 in the lung and spleen and n = 5–8 in the mLN from four mice with image duplicates). In E, data are represented by the median ± interquartile range and in F by the mean ± SEM. P values were calculated with Kruskal–Wallis and Dunn’s multiple comparison test in E and with two-way ANOVA with Tukey’s test in F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: The Journal of Experimental Medicine

    Article Title: Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation

    doi: 10.1084/jem.20252201

    Figure Lengend Snippet: CAlleR 8 murine Treg tissue–specific homing. (A) Experimental design of murine CAlleR 8 GFP + and CAR A2 GFP + Treg production. (B) Representative plots of Treg phenotype and transduction efficiency after 7 days of expansion. (C) Experimental design of the allergic airway inflammation mouse model and adoptive Treg transfer. (D) Representative images of CAlleR 8 and CAR A2 Tregs in the mLNs, lung, and spleen of mice exposed to PBS or BPE. White bars represent the scale of 20 μm, and small images show fluorescence channels of the magnified region outlined in white squares. (E) Cumulative data of detection of GFP + cells/mm2 in each organ ( n = 8 in the lung and spleen and n = 5–8 in mLN from four mice with image duplicates). (F) Cumulative data of the percentage of GFP + cells interacting with CD11c + , B220 + APCs or with none of them (no CD11c + /B220 + contact) for each organ ( n = 8 in the lung and spleen and n = 5–8 in the mLN from four mice with image duplicates). In E, data are represented by the median ± interquartile range and in F by the mean ± SEM. P values were calculated with Kruskal–Wallis and Dunn’s multiple comparison test in E and with two-way ANOVA with Tukey’s test in F. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: After blocking, cells were washed and extracellular staining was performed for 30 min at 4°C with the following antibodies: anti-mouse CD3 (145-2C11), PE-Cy7 (1:250 dilution) and APC-Cy7 (1:100 dilution), 552774; BD Biosciences (RRID:AB_394460) and 561042 (RRID:AB_2034003), respectively; anti-mouse CD4 (RM4-5), PerCP-Cy5.5 (1:300 dilution) and APC (1:250 dilution), 561090 and 553051; BD Biosciences, respectively; anti-mouse CD8a (53-6.7), FITC (1:100 dilution) and Pacific Blue (1:400 dilution), 553030 and 558106; BD Biosciences, respectively; anti-mouse CD25 (PC61.5), PE (1:200 dilution), 12-0251-83; Invitrogen; anti-mouse CD25 (PC61), PerCP-Cy5.5 (1:250 dilution), 551071; BD Biosciences; anti-mouse CD44 (IM7), FITC (1:100 dilution), 553133; BD Biosciences; anti-mouse CD45 (30-F11), PE-Cy7 (1:250), 552848; BD Biosciences; anti-mouse CD45.2 (104), AF700 (1:100 dilution), 109821; BioLegend; anti-mouse CD69 (H1.2F3), PE (1:400 dilution), 553237; BD Biosciences; anti-mouse CD86 (GL1), PE (1:250 dilution), 553692; BD Biosciences; anti-mouse CD90.1 (Thy1.1; OX-7), PerCP-Cy5.5 (1:250 dilution), 557266; BD Biosciences; anti-mouse CD90.1 (Thy1.1; REA838), FITC (1:500 dilution), 130-112-872; Miltenyi Biotech; anti-mouse CD11c (HL3), APC (1:100 dilution), 550261; BD Biosciences; anti-mouse CD11c (N418), APC-Cy7 (1:600 dilution), 117323; BioLegend; anti-mouse CD11b (M1/70), PECy7 (1:600 dilution), 561098; BD Biosciences; anti-mouse MHC-II (M5/114.15.2), AF700 (1:1,000 dilution), 107621; BioLegend; anti-mouse F480 (BM8), PerCP (1:100 dilution), 123126; BioLegend; anti-mouse Ly6C (HK1.4), Pacific Blue (1:1,000 dilution), 128013; BioLegend; anti-mouse SiglecF (E50-2440), PE (1:100 dilution), 562068; BD Biosciences; anti-mouse Ly6G (1A8), PerCP Cy5.5 (1:100 dilution), 560602; BD Biosciences; biotinylated rBet v1 (1 μg/ml); streptavidin, APC (1:500 dilution) and PE (1:1,000 dilution), 554067 and 554061; BD Biosciences, respectively; Aqua (Live/Dead), AmCyan (1:1,000 dilution), L34957 ; Invitrogen; DAPI (Live/Dead), Invitrogen (1:2,500 dilution), D1306.

    Techniques: Transduction, Fluorescence, Comparison

    SL disA increases the antigen-presentation capacity of dendritic cells (A) IFN-β levels in BMDC supernatants from media, SL, SL disA , and SL disA +H151 groups. (B, C) BMDCs double-stained with MHC II and CD11c were analyzed by flow cytometry (B), and CD11c + MHCII + cells are shown in the statistical graph (C). Data were expressed as mean ± SEM, n = 3. ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; one-way ANOVA with Tukey’s multiple comparisons tests.

    Journal: Molecular Therapy Oncology

    Article Title: Engineered Salmonella -mediated c-di-AMP delivery activates STING to remodel the tumor microenvironment

    doi: 10.1016/j.omton.2026.201185

    Figure Lengend Snippet: SL disA increases the antigen-presentation capacity of dendritic cells (A) IFN-β levels in BMDC supernatants from media, SL, SL disA , and SL disA +H151 groups. (B, C) BMDCs double-stained with MHC II and CD11c were analyzed by flow cytometry (B), and CD11c + MHCII + cells are shown in the statistical graph (C). Data were expressed as mean ± SEM, n = 3. ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; one-way ANOVA with Tukey’s multiple comparisons tests.

    Article Snippet: Cells were subsequently stained with fluorochrome-conjugated antibodies targeting surface markers, including FITC anti-mouse CD11c (clone N418, Elabscience Biotechnology Co., Ltd.) and PE-Cy7 anti-mouse MHC II (clone M5/114, Elabscience Biotechnology Co., Ltd.), and analyzed using a CytoFLEX cytometer (Beckman Coulter, Brea, CA, USA).

    Techniques: Immunopeptidomics, Staining, Flow Cytometry

    FAM134B-mediated ER-phagy downregulates sepsis-induced ferroptosis to protect the immune response of DCs. Two types of mice were adopted the severe CLP. Mice in the control group were defined as a sham operation. A. The percentage of co-stimulatory phenotypes expressed on DCs was measured by flow cytometry. B. DCs from hemophthalmia of CLP mice were cocultured with CD4 + T cells stained with Con A, and then T-cell proliferation induced by DCs was measured by flow cytometry. C. The release of inflammatory cytokines reflecting the degree of DC maturity and secretion was detected by ELISA after CLP. D. The survival rates of WT mice (n = 11) and FAM134B -/- mice (n = 12) were monitored at the indicated time points. E-G. The conditional knockout of FAM134B targeted for splenic DC in mouse (CD11c cre FAM134B fl/fl ) was structured and then underwent CLP procedure. DCs immune functions was measured by Flow Cytometry and survival rates of septic mice were analyzed. Data from three independent experiments were exhibited as the mean ± SD (n = 3 per group). Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 vs. the WT-Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. the FAM134B -/- -Sham group; & P < 0.05, && P < 0.01, &&& P < 0.001 as the FAM134B -/- -CLP group vs. the WT-CLP group.

    Journal: Journal of Advanced Research

    Article Title: The immune regulation and signaling transduction of FAM134B-mediated endoplasmic reticulum-phagy in ferroptosis of dendritic cells after sepsis

    doi: 10.1016/j.jare.2025.07.058

    Figure Lengend Snippet: FAM134B-mediated ER-phagy downregulates sepsis-induced ferroptosis to protect the immune response of DCs. Two types of mice were adopted the severe CLP. Mice in the control group were defined as a sham operation. A. The percentage of co-stimulatory phenotypes expressed on DCs was measured by flow cytometry. B. DCs from hemophthalmia of CLP mice were cocultured with CD4 + T cells stained with Con A, and then T-cell proliferation induced by DCs was measured by flow cytometry. C. The release of inflammatory cytokines reflecting the degree of DC maturity and secretion was detected by ELISA after CLP. D. The survival rates of WT mice (n = 11) and FAM134B -/- mice (n = 12) were monitored at the indicated time points. E-G. The conditional knockout of FAM134B targeted for splenic DC in mouse (CD11c cre FAM134B fl/fl ) was structured and then underwent CLP procedure. DCs immune functions was measured by Flow Cytometry and survival rates of septic mice were analyzed. Data from three independent experiments were exhibited as the mean ± SD (n = 3 per group). Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001 vs. the WT-Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. the FAM134B -/- -Sham group; & P < 0.05, && P < 0.01, &&& P < 0.001 as the FAM134B -/- -CLP group vs. the WT-CLP group.

    Article Snippet: Spleen CD11c + (N418) and CD4 + T cell (L3T4) MicroBeads have been obtained from Miltenyi Biological GmbH (Bergisch Gladbach, Germany).

    Techniques: Control, Flow Cytometry, Staining, Enzyme-linked Immunosorbent Assay, Knock-Out